

Ambulatory Care > Referral Management > Musculoskeletal Conditions > Connective Tissue Disorders, Inflammatory Arthritis, and Spondyloarthropathies - Referral Management (R-0062)

Connective Tissue Disorders, Inflammatory Arthritis, and Spondyloarthropathies - Referral Management

RMG: R-0062 (AC)

[Link to Codes](#)

MCG Health
Ambulatory Care
30th Edition

- Clinical Indications
- Evidence Summary
 - Criteria
 - Rationale
 - Related CMS Coverage Guidance
- References
- Footnotes
- Codes

Clinical Indications

- Referral for connective tissue disorders, inflammatory arthritis, and spondyloarthropathies may be indicated for **1 or more** of the following(1)(2)(3)(4)(5)(6):
 - ☐ Emergent evaluation or management of **1 or more** of the following:
 - Acute chloroquine or hydroxychloroquine toxicity, suspected (eg, delirium, heart block, myopathy, tonic-clonic seizures)(7)(8)
 - Chest pain(9)
 - Giant cell arteritis (ie, temporal arteritis), suspected, as indicated by **1 or more** of the following(9)(10)(11):
 - Cranial nerve palsy
 - Funduscopic examination abnormal
 - Headache, typically described as abrupt-onset and unilateral
 - Headache with scalp tenderness and acute encephalopathy(12)(13)
 - Jaw or tongue claudication
 - Serum ESR and/or C-reactive protein elevated
 - Temporal artery tenderness to palpation
 - Visual changes
 - Myocardial infarction(9)
 - Neuropsychiatric manifestation (eg, chorea, myelopathy, psychosis, seizures)(14)
 - Pericarditis or pericardial effusion(15)
 - Pulmonary embolism(16)
 - Pulmonary hemorrhage (eg, blood-stained sputum, gross hemoptysis, radiographic infiltrates)(15)(17)

- Renal crisis (ie, acute renal failure, malignant hypertension)(15)
- Septic arthritis, known or suspected(18)(19)(20)(21)
- Spinal fracture in patient with ankylosing spondylitis(22)
- Visual loss (eg, uveitis)
- Behavioral health referral for evaluation or management of psychosocial issues(23)
- Cardiology referral for evaluation or management of cardiovascular complications (eg, coronary artery disease, hypertension, hypertriglyceridemia)(8)(24)(25)(26)(27)(28)(29)
- Dermatology referral for evaluation or management of skin lesions (eg, psoriasis)(30)(31)
- Gastroenterology referral for evaluation or management of gastrointestinal manifestations (eg, gastrointestinal dysmotility, inflammatory bowel disease, autoimmune hepatitis)(32)(33)(34)(35)(36)(37)
- General surgery referral for biopsy of area of suspected involvement (eg, lymph node, muscle, nerve, temporal artery)(33)(38)(39)(40)(41)(42)
- Hematology referral for evaluation or management of hematologic complications (eg, antiphospholipid syndrome, bleeding, hemolytic anemia)(43)(44)(45)
- Infectious disease referral for evaluation or management of infection in prosthetic joint(37)(46)
- Nephrology referral for evaluation or management of renal complications (eg, abnormal urine sediment, proteinuria, lupus nephritis)(47)(48)(49)(50)(51)
- Neurology referral for evaluation or management of neurologic manifestations (eg, symmetric proximal muscle weakness, need for electromyography or nerve conduction studies)(8)(33)(41)(52)
- Neurosurgery referral for biopsy of muscle or nerve(33)(38)(41)
- ☐ Obstetrics and gynecology referral for evaluation or management of **1 or more** of the following:
 - Genital ulcer (eg, Behcet disease)(53)
 - Pregnant patient or patient desiring to become pregnant(54)(55)
 - Recurrent pregnancy loss (eg, antiphospholipid syndrome)(43)(56)
- Occupational therapy referral for evaluation or management of joint complications (eg, hand function or joint protection)
- ☐ Ophthalmology referral for evaluation or management of **1 or more** of the following:
 - Biopsy of temporal artery needed(57)
 - Chloroquine or hydroxychloroquine use, and need for baseline examination or monitoring for retinopathy(58)
 - Eye manifestations (eg, uveitis, iritis, scleritis)(26)(59)(60)(61)
- ☐ Orthopedic surgery referral for evaluation or management of **1 or more** of the following:
 - Extensor tendon rupture (eg, from rheumatoid arthritis)(46)
 - Infection in joint(46)
 - Joint aspiration or injection needed and difficult to perform[A]
 - Joint fusion (ie, arthrodesis)(64)
 - Joint replacement (ie, arthroplasty)(22)(64)
 - Metacarpophalangeal capsulotomy (scleroderma)(64)
 - Nerve entrapment (eg, carpal tunnel syndrome secondary to joint destruction)(46)
 - Severe thoracolumbar kyphosis (eg, with ankylosing spondylosis)(22)
 - Synovectomy (eg, for rheumatoid arthritis)
- Otorhinolaryngology referral for biopsy (eg, minor labial salivary gland, temporal artery)(42)(65)(66)
- Physical therapy referral for evaluation or management of joint complications (eg, joint range of motion, strengthening, splints)(67)(68)(69)(70)
- Podiatry referral for evaluation or management of foot complications (eg, for patients with rheumatoid arthritis)
- ☐ Pulmonology referral for evaluation or management of **1 or more** of the following:
 - Dyspnea with unclear etiology(71)(72)
 - Hemoptysis

- Incentive spirometry or deep-breathing exercises (eg, for ankylosing spondylitis)
- Interstitial lung disease (eg, systemic sclerosis, rheumatoid arthritis)(71)(73)(74)(75)
- Pleural effusion
- Pulmonary arterial hypertension (eg, systemic sclerosis)(71)(76)

☐ Rheumatology referral for evaluation or management of **1 or more** of the following:

- Ankylosing spondylitis(77)(78)(79)(80)
- Antiphospholipid syndrome(43)
- Arthritis in patient with inflammatory bowel disease(81)
- Behcet disease (eg, eye, skin, or mucous membrane involvement)(53)
- Corticosteroid injection needed
- Crystalline arthropathy (eg, pseudogout)(82)
- Dermatomyositis(31)(83)(84)
- Diagnosis unclear despite performance of standard laboratory testing and imaging studies(85)(86)
- Disease-modifying antirheumatic drug needed (eg, tumor necrosis factor inhibitor, methotrexate)(37)(87)(88)
- Fever of unknown origin(89)
- Giant cell arteritis(9)(10)(11)
- Gouty arthritis
- IgG4-related disease(90)(91)
- Inflammatory arthritis in one or more joints(46)(92)(93)
- Joint aspiration or injection needed and difficult to perform[A]
- Juvenile idiopathic arthritis[B](95)(96)(97)(98)
- Multisystem involvement (eg, pericardial or pleural effusion)(99)
- Nonradiographic axial spondyloarthritis(81)(100)
- Polymyalgia rheumatica unresponsive to corticosteroids(101)
- Polymyositis
- Psoriatic arthritis(26)(102)(103)(104)(105)(106)
- Raynaud phenomenon(107)(108)
- Reactive arthritis (Reiter syndrome)(60)(109)
- Rheumatoid arthritis(37)(46)(99)(110)(111)
- Sarcoidosis(112)(113)
- Seronegative spondyloarthropathy
- Sjogren syndrome(66)(71)(114)(115)
- Systemic lupus erythematosus(1)(116)(117)(118)
- Systemic sclerosis (ie, scleroderma)(76)(119)(120)
- Vasculitis(9)(47)(121)

- Vascular surgery referral for temporal artery biopsy(10)(11)

Evidence Summary

Criteria

The evidence for the clinical indications found in this guideline includes 99 published peer reviewed articles, 20 specialty society or other evidence-based guidelines, 1 Cochrane systematic review, and 1 book section.

Rationale

Use of this MCG care guideline helps the clinician identify specific complex factors of a patient's condition that may need specialist consultation. It provides evidence-based clinical criteria to help decide when a patient should be referred to a specialist, ensuring timely specialty care. Additionally, this guideline can help limit unnecessary differences in treatment, like variable criteria for emergency or subspecialist referral, thereby promoting equal access and quality of care for similar patients, regardless of location, facility, or clinician.

Related CMS Coverage Guidance

None applicable

References

1. Fanouriakis A, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. *Annals of the Rheumatic Diseases* 2024;83(1):15-29. DOI: 10.1136/ard-2023-224762. (Reaffirmed 2025 Jul) [Context Link 1, 2] View abstract...
2. Desbois AC, Cacoub P. Systemic sclerosis: An update in 2016. *Autoimmunity Reviews* 2016;15(5):417-426. DOI: 10.1016/j.autrev.2016.01.007. [Context Link 1] View abstract...
3. Dimachkie MM, Barohn RJ, Amato AA. Idiopathic inflammatory myopathies. *Neurologic Clinics* 2014;32(3):595-628, vii. DOI: 10.1016/j.ncl.2014.04.007. [Context Link 1] View abstract...
4. Ward MM, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis & Rheumatology* (Hoboken, N.J.) 2019;71(10):1599-1613. DOI: 10.1002/art.41042. (Reaffirmed 2025 May) [Context Link 1] View abstract...
5. Spondyloarthritis in Over 16s: Diagnosis and Management. NICE Guidance NG65 [Internet] National Institute for Health and Care Excellence. 2017 Jun Accessed at: <https://www.nice.org.uk/guidance/>. [created 2017; accessed 2024 Oct 01] [Context Link 1]
6. Sammaritano LR, et al. 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. *Arthritis Care & Research* 2025;DOI: 10.1002/acr.25690. [Context Link 1] View abstract...
7. Della Porta A, Bornstein K, Coye A, Montrieff T, Long B, Parris MA. Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. *American Journal of Emergency Medicine* 2020;38(10):2209-2217. DOI: 10.1016/j.ajem.2020.07.030. [Context Link 1] View abstract...
8. Doyno C, Sobieraj DM, Baker WL. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. *Clinical Toxicology* 2021;59(1):12-23. DOI: 10.1080/15563650.2020.1817479. [Context Link 1, 2, 3] View abstract...
9. Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. *Arthritis & Rheumatology* (Hoboken, N.J.) 2021;73(8):1349-1365. DOI: 10.1002/art.41774. (Reaffirmed 2025 Jul) [Context Link 1, 2, 3, 4, 5] View abstract...
10. Mackie SL, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. *Rheumatology* 2020;59(3):e1-e23. DOI: 10.1093/rheumatology/kez672. (Reaffirmed 2025 Jul) [Context Link 1, 2, 3] View abstract...
11. Chatterjee S, Flamm SD, Tan CD, Rodriguez ER. Clinical diagnosis and management of large vessel vasculitis: giant cell arteritis. *Current Cardiology Reports* 2014;16(7):498. DOI: 10.1007/s11886-014-0498-z. [Context Link 1, 2, 3] View abstract...
12. Erkinen MG, Berkowitz AL. A clinical approach to diagnosing encephalopathy. *American Journal of Medicine* 2019;132(10):1142-1147. DOI: 10.1016/j.amjmed.2019.07.001. [Context Link 1] View abstract...
13. Baig IF, Pascoe AR, Kini A, Lee AG. Giant cell arteritis: early diagnosis is key. *Eye and Brain* 2019;11:1-12. DOI: 10.2147/EB.S170388. [Context Link 1] View abstract...

14. Tunnicliffe DJ, Singh-Grewal D, Kim S, Craig JC, Tong A. Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines. *Arthritis Care & Research* 2015;67(10):1440-1452. DOI: 10.1002/acr.22591. [Context Link 1] View abstract...
15. Rose J. Autoimmune connective tissue diseases: systemic lupus erythematosus and rheumatoid arthritis. *Emergency Medicine Clinics of North America* 2022;40(1):179-191. DOI: 10.1016/j.emc.2021.09.003. [Context Link 1, 2, 3] View abstract...
16. Choi HK, Rho YH, Zhu Y, Cea-Soriano L, Avina-Zubieta JA, Zhang Y. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. *Annals of the Rheumatic Diseases* 2013;72(7):1182-1187. DOI: 10.1136/annrheumdis-2012-201669. [Context Link 1] View abstract...
17. Al-Adhoubi NK, Bystrom J. Systemic lupus erythematosus and diffuse alveolar hemorrhage, etiology and novel treatment strategies. *Lupus* 2020;29(4):355-363. DOI: 10.1177/0961203320903798. [Context Link 1] View abstract...
18. Ohi CA. Infectious arthritis of native joints. In: Bennett JE, Dolin R, Blaser MJ, editors. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 9th ed. Philadelphia, PA: Elsevier; 2020:1400-1417.e6. [Context Link 1]
19. Donders CM, Spaans AJ, van Wering H, van Bergen CJ. Developments in diagnosis and treatment of paediatric septic arthritis. *World Journal of Orthopedics* 2022;13(2):122-130. DOI: 10.5312/wjo.v13.i2.122. [Context Link 1] View abstract...
20. Kim HW, Han M, Jung I, Ahn SS. Incidence of septic arthritis in patients with ankylosing spondylitis and seropositive rheumatoid arthritis following TNF-inhibitor therapy. *Rheumatology* 2023;62(8):2740-2747. DOI: 10.1093/rheumatology/keac721. [Context Link 1] View abstract...
21. Qiao L, Xu D, Zhao Y, Zeng X, Zhang F. A retrospective study of joint infections in patients with systemic lupus erythematosus. *Clinical Rheumatology* 2017;36(9):2011-2017. DOI: 10.1007/s10067-017-3738-y. [Context Link 1] View abstract...
22. Braun J, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Annals of the Rheumatic Diseases* 2011;70(6):896-904. DOI: 10.1136/ard.2011.151027. (Reaffirmed 2025 Jun) [Context Link 1, 2, 3] View abstract...
23. Kosola S, Relas H. Patients with psychiatric diagnoses have lower quality of life than other patients with juvenile rheumatic disease: a prospective study. *Rheumatology* 2021;60(12):5560-5566. DOI: 10.1093/rheumatology/keab150. [Context Link 1] View abstract...
24. Juarez M, et al. Cardiovascular risk factors in women with primary Sjogren's syndrome: United Kingdom primary Sjogren's syndrome registry results. *Arthritis Care & Research* 2014;66(5):757-764. [Context Link 1] View abstract...
25. Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. *Annals of Internal Medicine* 2015;163(6):409-416. DOI: 10.7326/M14-2470. [Context Link 1] View abstract...
26. Menter A, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. *Journal of the American Academy of Dermatology* 2020;82(1):161-201. DOI: 10.1016/j.jaad.2019.08.049. (Reaffirmed 2025 Jun) [Context Link 1, 2, 3] View abstract...
27. Kontzias A, Barkhodari A, Yao Q. Pericarditis in systemic rheumatologic diseases. *Current Cardiology Reports* 2020;22(11):142. DOI: 10.1007/s11886-020-01415-w. [Context Link 1] View abstract...
28. Writing Committee Members, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. *Journal of the American College of Cardiology* 2023;82(9):833-955. DOI: 10.1016/j.jacc.2023.04.003. [Context Link 1] View abstract...
29. Cheng RK, et al. Diagnosis and management of cardiac sarcoidosis: a scientific statement from the American Heart Association. *Circulation* 2024;149(21):e119-e1216. DOI: 10.1161/CIR.0000000000001240. [Context Link 1] View abstract...
30. Alves F, Goncalo M. Suspected inflammatory rheumatic diseases in patients presenting with skin rashes. *Best Practice and Research. Clinical Rheumatology* 2019;33(4):101440. DOI: 10.1016/j.berh.2019.101440. [Context Link 1] View abstract...
31. Hu T, Vinik O. Dermatomyositis and malignancy. *Canadian Family Physician* 2019;65(6):409-411. [Context Link 1, 2] View abstract...
32. Gyger G, Baron M. Systemic sclerosis: gastrointestinal disease and its management. *Rheumatic Diseases Clinics of North America* 2015;41(3):459-473. DOI: 10.1016/j.rdc.2015.04.007. [Context Link 1] View abstract...
33. Walters J, Baborie A. Muscle biopsy: what and why and when? *Practical Neurology* 2020;20(5):385-395. DOI: 10.1136/practneurol-2019-002465. [Context Link 1, 2, 3, 4] View abstract...

34. Adiga A, Nugent K. Lupus hepatitis and autoimmune hepatitis (lupoid hepatitis). *American Journal of the Medical Sciences* 2017;353(4):329-335. DOI: 10.1016/j.amjms.2016.10.014. [Context Link 1] View abstract...
35. Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T. Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. *World Journal of Gastroenterology* 2019;25(18):2162-2176. DOI: 10.3748/wjg.v25.i18.2162. [Context Link 1] View abstract...
36. Mack CL, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases. *Hepatology* 2020;72(2):671-722. DOI: 10.1002/hep.31065. (Reaffirmed 2025 Jul) [Context Link 1] View abstract...
37. Fraenkel L, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care & Research* 2021;73(7):924-939. DOI: 10.1002/acr.24596. (Reaffirmed 2025 Mar) [Context Link 1, 2, 3, 4] View abstract...
38. Goel J, Anadure RK, Nair MD, Yasha TC. A study correlating nerve biopsy with clinical diagnosis and its impact on improving management in peripheral neuropathies. *Interdisciplinary Neurosurgery : Advanced techniques and Case Management* 2021;25(101237):Online. DOI: 10.1016/j.inat.2021.101237. [Context Link 1, 2]
39. Salamat S, et al. Kikuchi-Fujimoto disease and prognostic implications. *Head and Neck Pathology* 2020;14(1):272-275. DOI: 10.1007/s12105-019-01026-0. [Context Link 1] View abstract...
40. Afzal W, Arab T, Ullah T, Teller K, Doshi KJ. Generalized lymphadenopathy as presenting feature of systemic lupus erythematosus: case report and review of the literature. *Journal of Clinical Medicine Research* 2016;8(11):819-823. DOI: 10.14740/jocmr2717w. [Context Link 1] View abstract...
41. Nathani D, et al. Nerve biopsy: Current indications and decision tools. *Muscle and Nerve* 2021;64(2):125-139. DOI: 10.1002/mus.27201. [Context Link 1, 2, 3] View abstract...
42. Micieli JA, Micieli R, Margolin EA. A review of specialties performing temporal artery biopsies in Ontario: a retrospective cohort study. *CMAJ Open* 2015;3(3):E281-5. DOI: 10.9778/cmajo.20140108. [Context Link 1, 2] View abstract...
43. Committee on Practice Bulletins-Obstetrics, American College of Obstetricians and Gynecologists. Antiphospholipid syndrome: practice bulletin No. 132. *Obstetrics & Gynecology* 2012 (ACOG reaffirmed 2025);120(6):1514-21. DOI: 10.1097/01.AOG.0000423816.39542.0f. (Reaffirmed 2025 Jun) [Context Link 1, 2, 3] View abstract...
44. Noureldine MHA, Nour-Eldine W, Khamashta MA, Uthman I. Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome. *Seminars in Arthritis and Rheumatism* 2019;48(5):860-866. DOI: 10.1016/j.semarthrit.2018.08.004. [Context Link 1] View abstract...
45. Artoni A, et al. Hemostatic abnormalities in patients with Ehlers-Danlos syndrome. *Journal of Thrombosis and Haemostasis* 2018;16(12):2425-2431. DOI: 10.1111/jth.14310. [Context Link 1] View abstract...
46. Rheumatoid Arthritis in Adults: Management. NICE Guidance NG100 [Internet] National Institute for Health and Care Excellence. 2020 Oct Accessed at: <https://www.nice.org.uk/guidance>. [accessed 2025 Jan 27] [Context Link 1, 2, 3, 4, 5, 6]
47. Biddle K, et al. The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis. *Rheumatology* 2025;DOI: 10.1093/rheumatology/keaf240. (Reaffirmed 2025 Jul 10) [Context Link 1, 2] View abstract...
48. Walters GD, Willis NS, Cooper TE, Craig JC. Interventions for renal vasculitis in adults. *Cochrane Database of Systematic Reviews* 2020, Issue 1. Art. No.: CD003232. DOI: 10.1002/14651858.CD003232.pub4. [Context Link 1] View abstract...
49. Fanouriakis A, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. *Annals of the Rheumatic Diseases* 2020;79(6):713-723. DOI: 10.1136/annrheumdis-2020-216924. (Reaffirmed 2025 Jun) [Context Link 1] View abstract...
50. Siegel CH, Sammaritano LR. Systemic lupus erythematosus: a review. *Journal of the American Medical Association* 2024;331(17):1480-1491. DOI: 10.1001/jama.2024.2315. [Context Link 1] View abstract...
51. Sammaritano LR, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. *Arthritis Care & Research* 2025;DOI: 10.1002/acr.25528. (Reaffirmed 2025 May) [Context Link 1] View abstract...
52. Pavlakis PP. Rheumatologic disorders and the nervous system. *Continuum : Lifelong Learning in Neurology* 2020;26(3):591-610. DOI: 10.1212/CON.0000000000000856. [Context Link 1] View abstract...
53. Hatemi G, Yazici Y, Yazici H. Behcet's syndrome. *Rheumatic Diseases Clinics of North America* 2013;39(2):245-261. DOI: 10.1016/j.rdc.2013.02.010. [Context Link 1, 2] View abstract...

54. Brouwer J, Hazes JM, Laven JS, Dolhain RJ. Fertility in women with rheumatoid arthritis: influence of disease activity and medication. *Annals of the Rheumatic Diseases* 2015;74(10):1836-1841. DOI: 10.1136/annrheumdis-2014-205383. [Context Link 1] View abstract...
55. Vanni VS, De Lorenzo R, Privitera L, Canti V, Vigano P, Rovere-Querini P. Safety of fertility treatments in women with systemic autoimmune diseases (SADs). *Expert Opinion on Drug Safety* 2019;18(9):841-852. DOI: 10.1080/14740338.2019.1636964. [Context Link 1] View abstract...
56. Uthman I, Noureldine MHA, Ruiz-Irastorza G, Khamashta M. Management of antiphospholipid syndrome. *Annals of the Rheumatic Diseases* 2019;78(2):155-161. DOI: 10.1136/annrheumdis-2018-213846. [Context Link 1] View abstract...
57. Golenbiewski J, Burden S, Wolfe RM. Temporal artery biopsy. *Best Practice and Research. Clinical Rheumatology* 2023;37(1):Online. DOI: 10.1016/j.berh.2023.101833. [Context Link 1] View abstract...
58. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). *Ophthalmology* 2016;123(6):1386-1394. DOI: 10.1016/j.ophtha.2016.01.058. (Reaffirmed 2025 Jun) [Context Link 1] View abstract...
59. Cornec D, Jamin C, Pers JO. Sjogren's syndrome: where do we stand, and where shall we go? *Journal of Autoimmunity* 2014;51:109-114. DOI: 10.1016/j.jaut.2014.02.006. [Context Link 1] View abstract...
60. Carlin EM, Ziza JM, Keat A, Janier M. 2014 European Guideline on the management of sexually acquired reactive arthritis. *International Journal of STD and AIDS* 2014;25(13):901-912. DOI: 10.1177/0956462414540617. [Context Link 1, 2] View abstract...
61. Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. *Clinical Immunology* 2019;211:Online. DOI: 10.1016/j.clim.2019.108322. [Context Link 1] View abstract...
62. Dalbeth N, Merriman TR, Stamp LK. Gout. *Lancet* 2016;388(10055):2039-2052. DOI: 10.1016/S0140-6736(16)00346-9. [Context Link 1] View abstract...
63. Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. *New England Journal of Medicine* 2016;374(26):2575-2584. DOI: 10.1056/NEJMra1511117. [Context Link 1] View abstract...
64. Beldner S, Rabinovich RV, Polatsch DB. Scleroderma of the hand: evaluation and treatment. *Journal of the American Academy of Orthopedic Surgeons* 2020;28(16):e686-e695. DOI: 10.5435/JAAOS-D-19-00547. [Context Link 1, 2, 3] View abstract...
65. Parreau S, et al. Temporal artery biopsy: A technical guide and review of its importance and indications. *Survey of Ophthalmology* 2023;68(1):104-112. DOI: 10.1016/j.survophthal.2022.08.008. [Context Link 1] View abstract...
66. Price EJ, et al. British Society for Rheumatology guideline on management of adult and juvenile onset Sjogren disease. *Rheumatology* 2024;Online. DOI: 10.1093/rheumatology/keae152. [Context Link 1, 2] View abstract...
67. Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. *New England Journal of Medicine* 2014;371(1):50-57. DOI: 10.1056/NEJMcp1214825. [Context Link 1] View abstract...
68. Peter WF, Swart NM, Meerhoff GA, Vliet Vlieland TPM. Clinical practice guideline for physical therapist management of people with rheumatoid arthritis. *Physical Therapy* 2021;101(8):pzab127. DOI: 10.1093/ptj/pzab127. [Context Link 1] View abstract...
69. Teuwen MMH, et al. Effectiveness of longstanding exercise therapy compared with usual care for people with rheumatoid arthritis and severe functional limitations: a randomised controlled trial. *Annals of the Rheumatic Diseases* 2024;83(4):437-445. DOI: 10.1136/ard-2023-224912. [Context Link 1] View abstract...
70. van Wissen MAT, et al. One-year effectiveness of long-term exercise therapy in people with axial spondyloarthritis and severe functional limitations. *Rheumatology* 2024;Online. DOI: 10.1093/rheumatology/keae323. [Context Link 1] View abstract...
71. Lee AS, et al. Consensus guidelines for evaluation and management of pulmonary disease in Sjogren's. *Chest* 2021;159(2):683-698. DOI: 10.1016/j.chest.2020.10.011. [Context Link 1, 2, 3, 4] View abstract...
72. Danve A. Thoracic manifestations of ankylosing spondylitis, inflammatory bowel disease, and relapsing polychondritis. *Clinics in Chest Medicine* 2019;40(3):599-608. DOI: 10.1016/j.ccm.2019.05.006. [Context Link 1] View abstract...
73. Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). *Respiratory Research* 2019;20(1):13. DOI: 10.1186/s12931-019-0980-7. [Context Link 1] View abstract...
74. Mira-Avendano I, et al. Interstitial lung disease and other pulmonary manifestations in connective tissue diseases. *Mayo Clinic Proceedings* 2019;94(2):309-325. DOI: 10.1016/j.mayocp.2018.09.002. [Context Link 1] View abstract...

75. Guler SA, Scheschkowski T, Renner A, Kampf L, Gasser M, Maurer B. Interdisciplinary diagnosis and management of patients with interstitial lung disease and connective tissue disease. *Chest* 2024;166(2):352-361. DOI: 10.1016/j.chest.2024.02.045. [Context Link 1] View abstract...
76. Torok KS. Pediatric scleroderma: systemic or localized forms. *Pediatric Clinics of North America* 2012;59(2):381-405. DOI: 10.1016/j.pcl.2012.03.011. [Context Link 1, 2] View abstract...
77. Evans J, Negoescu A. Early recognition pivotal in the management of spondyloarthritis. *Practitioner* 2017;261(1810):11-15. [Context Link 1]
78. Smolen JS, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Annals of the Rheumatic Diseases* 2018;77(1):3-17. DOI: 10.1136/annrheumdis-2017-211734. [Context Link 1] View abstract...
79. Murphy D. Early recognition and diagnosis of spondyloarthritis. *InnovAiT* 2018;11(8):444-447. [Context Link 1]
80. Danve A, Deodhar A. Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities. *Clinical Rheumatology* 2019;38(3):625-634. DOI: 10.1007/s10067-018-4397-3. [Context Link 1] View abstract...
81. Mease PJ. Suspecting and diagnosing the patient with spondyloarthritis and what to expect from therapy. *Medical Clinics of North America* 2021;105(2):325-339. DOI: 10.1016/j.mcna.2020.10.001. [Context Link 1, 2] View abstract...
82. Sidari A, Hill E. Diagnosis and treatment of gout and pseudogout for everyday practice. *Primary Care* 2018;45(2):213-236. DOI: 10.1016/j.pop.2018.02.004. [Context Link 1] View abstract...
83. Huber AM, et al. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. *Journal of Rheumatology* 2017;44(1):110-116. DOI: 10.3899/jrheum.160688. [Context Link 1] View abstract...
84. Enders FB, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. *Annals of the Rheumatic Diseases* 2017;76(2):329-340. DOI: 10.1136/annrheumdis-2016-209247. [Context Link 1] View abstract...
85. Watts RA. How to investigate multisystem disease. *Best Practice and Research. Clinical Rheumatology* 2014;28(6):831-843. DOI: 10.1016/j.berh.2015.04.011. [Context Link 1] View abstract...
86. Nagy G, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2022;81(1):20-33. DOI: 10.1136/annrheumdis-2021-220973. [Context Link 1] View abstract...
87. Lau CS, et al. APLAR rheumatoid arthritis treatment recommendations. *International Journal of Rheumatic Diseases* 2015;18(7):685-713. DOI: 10.1111/1756-185X.12754. [Context Link 1] View abstract...
88. Sieper J, Poddubny D. Axial spondyloarthritis. *Lancet* 2017;390(10089):73-84. DOI: 10.1016/S0140-6736(16)31591-4. [Context Link 1] View abstract...
89. Mulders-Manders CM, Simon A, Bleeker-Rovers CP. Rheumatologic diseases as the cause of fever of unknown origin. *Best Practice and Research. Clinical Rheumatology* 2016;30(5):789-801. DOI: 10.1016/j.berh.2016.10.005. [Context Link 1] View abstract...
90. Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease. *British Medical Journal* 2020;369:m1067. DOI: 10.1136/bmj.m1067. [Context Link 1] View abstract...
91. Lanzillotta M, et al. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. *Rheumatology* 2020;59(9):2435-2442. DOI: 10.1093/rheumatology/keaa221. [Context Link 1] View abstract...
92. Nguyen P, Julien AS, Bessette L, Fortin PR, Michou L. Sharing ongoing care with primary care physicians opens up opportunity for timelier and earlier care by rheumatologists for patients with new inflammatory polyarthritis. *Journal of Rheumatology* 2018;45(2):266-273. DOI: 10.3899/jrheum.170494. [Context Link 1] View abstract...
93. Foster ZJ, Day AL, Miller J. Polyarticular joint pain in adults: evaluation and differential diagnosis. *American Family Physician* 2023;107(1):42-51. [Context Link 1] View abstract...
94. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. *Lancet* 2011;377(9783):2138-2149. DOI: 10.1016/S0140-6736(11)60244-4. [Context Link 1] View abstract...
95. Ringold S, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. *Arthritis Care & Research* 2019;71(6):717-734. DOI: 10.1002/acr.23870. (Reaffirmed 2025 Mar) [Context Link 1] View abstract...

96. Sen ES, Clarke SL, Ramanan AV. The child with joint pain in primary care. *Best Practice and Research. Clinical Rheumatology* 2014;28(6):888-906. DOI: 10.1016/j.berh.2015.04.008. [Context Link 1] View abstract...
97. Lee JJY, Schneider R. Systemic Juvenile Idiopathic Arthritis. *Pediatric Clinics of North America* 2018;65(4):691-709. DOI: 10.1016/j.pcl.2018.04.005. [Context Link 1] View abstract...
98. Brunello F, et al. New insights on juvenile psoriatic arthritis. *Frontiers in Pediatrics* 2022;10:Online. DOI: 10.3389/fped.2022.884727. [Context Link 1] View abstract...
99. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. *Journal of the American Medical Association* 2018;320(13):1360-1372. DOI: 10.1001/jama.2018.13103. [Context Link 1, 2] View abstract...
100. Magrey MN, Danve AS, Ermann J, Walsh JA. Recognizing axial spondyloarthritis: a guide for primary care. *Mayo Clinic Proceedings* 2020;95(11):2499-2508. DOI: 10.1016/j.mayocp.2020.02.007. [Context Link 1] View abstract...
101. Dejaco C, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. *Annals of the Rheumatic Diseases* 2015;74(10):1799-1807. DOI: 10.1136/annrheumdis-2015-207492. (Reaffirmed 2025 Jun) [Context Link 1] View abstract...
102. Gisondi P, et al. Consensus on the management of patients with psoriatic arthritis in a dermatology setting. *Journal of the European Academy of Dermatology and Venereology: JEADV.* 2018;32(4):515-528. DOI: 10.1111/jdv.14741. [Context Link 1] View abstract...
103. Al Rayes H, et al. Consensus-based recommendations on the diagnosis, referral and clinical management of patients with psoriatic arthritis. *Rheumatology International* 2022;42(3):391-401. DOI: 10.1007/s00296-021-05029-5. [Context Link 1] View abstract...
104. Hioki T, Komine M, Ohtsuki M. Diagnosis and intervention in early psoriatic arthritis. *Journal of Clinical Medicine* 2022;11(7):Online. DOI: 10.3390/jcm11072051. [Context Link 1] View abstract...
105. Coates LC, et al. Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel. *Rheumatology* 2024;Online. DOI: 10.1093/rheumatology/keae172. [Context Link 1] View abstract...
106. Gossec L, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. *Annals of the Rheumatic Diseases* 2024;Online. DOI: 10.1136/ard-2024-225531. (Reaffirmed 2025 Mar) [Context Link 1] View abstract...
107. Pauling JD, Hughes M, Pope JE. Raynaud's phenomenon-an update on diagnosis, classification and management. *Clinical Rheumatology* 2019;38(12):3317-3330. DOI: 10.1007/s10067-019-04745-5. [Context Link 1] View abstract...
108. Herrick AL, Wigley FM. Raynaud's phenomenon. *Best Practice and Research. Clinical Rheumatology* 2020;34(1):Online. DOI: 10.1016/j.berh.2019.101474. [Context Link 1] View abstract...
109. Selmi C, Gershwin ME. Diagnosis and classification of reactive arthritis. *Autoimmunity Reviews* 2014;13(4-5):546-549. DOI: 10.1016/j.autrev.2014.01.005. [Context Link 1] View abstract...
110. Cush JJ. Rheumatoid arthritis: early diagnosis and treatment. *Medical Clinics of North America* 2021;105(2):355-365. DOI: 10.1016/j.mcna.2020.10.006. [Context Link 1] View abstract...
111. Serhal L, Lwin MN, Holroyd C, Edwards CJ. Rheumatoid arthritis in the elderly: characteristics and treatment considerations. *Autoimmunity Reviews* 2020;19(6):Online. DOI: 10.1016/j.autrev.2020.102528. [Context Link 1] View abstract...
112. Hasbani GE, Uthman I, Jawad AS. Musculoskeletal manifestations of sarcoidosis. *Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders* 2022;15:Online. DOI: 10.1177/11795441211072475. [Context Link 1] View abstract...
113. Llanos O, Hamzeh N. Sarcoidosis. *Medical Clinics of North America* 2019;103(3):527-534. DOI: 10.1016/j.mcna.2018.12.011. [Context Link 1] View abstract...
114. Mariette X, Criswell LA. Primary Sjogren's syndrome. *New England Journal of Medicine* 2018;378(10):931-939. DOI: 10.1056/NEJMcp1702514. [Context Link 1] View abstract...
115. Glennon P. Sjogren disease, new name, new guidelines: Key messages for primary care. *InnovAiT* 2024;17(11-12):Online. DOI: 10.1177/17557380241281472. [Context Link 1]
116. Aringer M, Johnson SR. Systemic lupus erythematosus classification and diagnosis. *Rheumatic Diseases Clinics of North America* 2021;47(3):501-511. DOI: 10.1016/j.rdc.2021.04.011. [Context Link 1] View abstract...

117. Keeling SO, et al. Canadian Rheumatology Association Recommendations for the assessment and monitoring of systemic lupus erythematosus. *Journal of Rheumatology* 2018;45(10):1426-1439. DOI: 10.3899/jrheum.171459. (Reaffirmed 2025 Jun) [Context Link 1] View abstract...
118. Hoi A, Igel T, Mok CC, Arnaud L. Systemic lupus erythematosus. *Lancet* 2024;403(10441):2323-2338. DOI: 10.1016/S0140-6736(24)00398-2. [Context Link 1] View abstract...
119. Jerjen R, Nikpour M, Krieg T, Denton CP, Saracino AM. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis. *Journal of the American Academy of Dermatology* 2022;87(5):937-954. DOI: 10.1016/j.jaad.2021.10.065. [Context Link 1] View abstract...
120. Del Galdo F, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. *Annals of the Rheumatic Diseases* 2024;Online. DOI: 10.1136/ard-2024-226430. (Reaffirmed 2025 Jul) [Context Link 1] View abstract...
121. Magri SJ, et al. Pan American League of Associations for Rheumatology Guidelines for the treatment of ANCA-associated vasculitis. *Lancet. Rheumatology*. 2023;5(8):Online. DOI: 10.1016/S2665-9913(23)00128-5. [Context Link 1] View abstract...

Footnotes

[A] Joint aspiration may be needed to rule out septic arthritis or crystal arthropathy, such as gout or pseudogout.(62)(63) [A in Context Link 1, 2]

[B] Juvenile idiopathic arthritis is not a single disease but encompasses all forms of inflammatory arthritis with onset before 16 years of age. It encompasses the previous term juvenile rheumatoid arthritis.(94) [B in Context Link 1]

Codes

ICD-10 Diagnosis: L40.50, L40.51, L40.52, L40.53, L40.54, L40.59, M02.30, M02.311, M02.312, M02.319, M02.321, M02.322, M02.329, M02.331, M02.332, M02.339, M02.341, M02.342, M02.349, M02.351, M02.352, M02.359, M02.361, M02.362, M02.369, M02.371, M02.372, M02.379, M02.38, M02.39, M02.80, M02.811, M02.812, M02.819, M02.821, M02.822, M02.829, M02.831, M02.832, M02.839, M02.841, M02.842, M02.849, M02.851, M02.852, M02.859, M02.861, M02.862, M02.869, M02.871, M02.872, M02.879, M02.88, M02.89, M02.9, M05.00, M05.011, M05.012, M05.019, M05.021, M05.022, M05.029, M05.031, M05.032, M05.039, M05.041, M05.042, M05.049, M05.051, M05.052, M05.059, M05.061, M05.062, M05.069, M05.071, M05.072, M05.079, M05.09, M05.10, M05.111, M05.112, M05.119, M05.121, M05.122, M05.129, M05.131, M05.132, M05.139, M05.141, M05.142, M05.149, M05.151, M05.152, M05.159, M05.161, M05.162, M05.169, M05.171, M05.172, M05.179, M05.19, M05.20, M05.211, M05.212, M05.219, M05.221, M05.222, M05.229, M05.231, M05.232, M05.239, M05.241, M05.242, M05.249, M05.251, M05.252, M05.259, M05.261, M05.262, M05.269, M05.271, M05.272, M05.279, M05.29, M05.30, M05.311, M05.312, M05.319, M05.321, M05.322, M05.329, M05.331, M05.332, M05.339, M05.341, M05.342, M05.349, M05.351, M05.352, M05.359, M05.361, M05.362, M05.369, M05.371, M05.372, M05.379, M05.39, M05.40, M05.411, M05.412, M05.419, M05.421, M05.422, M05.429, M05.431, M05.432, M05.439, M05.441, M05.442, M05.449, M05.451, M05.452, M05.459, M05.461, M05.462, M05.469, M05.471, M05.472, M05.479, M05.49, M05.50, M05.511, M05.512, M05.519, M05.521, M05.522, M05.529, M05.531, M05.532, M05.539, M05.541, M05.542, M05.549, M05.551, M05.552, M05.559, M05.561, M05.562, M05.569, M05.571, M05.572, M05.579, M05.59, M05.60, M05.611, M05.612, M05.619, M05.621, M05.622, M05.629, M05.631, M05.632, M05.639, M05.641, M05.642, M05.649, M05.651, M05.652, M05.659, M05.661, M05.662, M05.669, M05.671, M05.672, M05.679, M05.69, M05.70, M05.711, M05.712, M05.719, M05.721, M05.722, M05.729, M05.731, M05.732, M05.739, M05.741, M05.742, M05.749, M05.751, M05.752, M05.759, M05.761, M05.762, M05.769, M05.771, M05.772, M05.779, M05.79, M05.7A, M05.80, M05.811, M05.812, M05.819, M05.821, M05.822, M05.829, M05.831, M05.832, M05.839, M05.841, M05.842, M05.849, M05.851, M05.852, M05.859, M05.861, M05.862, M05.869, M05.871, M05.872, M05.879, M05.89, M05.8A, M05.9, M05.A, M06.00, M06.011, M06.012, M06.019, M06.021, M06.022, M06.029, M06.031, M06.032, M06.039, M06.041, M06.042, M06.049, M06.051, M06.052, M06.059, M06.061, M06.062, M06.069, M06.071, M06.072, M06.079, M06.08, M06.09, M06.0A, M06.1, M06.20, M06.211, M06.212, M06.219, M06.221, M06.222, M06.229, M06.231, M06.232, M06.239, M06.241, M06.242, M06.249, M06.251, M06.252, M06.259, M06.261, M06.262, M06.269, M06.271, M06.272, M06.279, M06.28, M06.29, M06.30, M06.311, M06.312, M06.319, M06.321, M06.322, M06.329, M06.331, M06.332, M06.339, M06.341, M06.342, M06.349, M06.351, M06.352, M06.359, M06.361, M06.362, M06.369, M06.371, M06.372, M06.379, M06.38, M06.39, M06.4, M06.80, M06.811, M06.812, M06.819, M06.821, M06.822, M06.829, M06.831, M06.832, M06.839, M06.841, M06.842, M06.849, M06.851, M06.852, M06.859, M06.861, M06.862, M06.869, M06.871, M06.872, M06.879, M06.88, M06.89, M06.8A, M06.9, M07.60, M07.611, M07.612, M07.619, M07.621, M07.622, M07.629, M07.631, M07.632, M07.639, M07.641, M07.642, M07.649, M07.651, M07.652, M07.659, M07.661, M07.662, M07.669, M07.671, M07.672, M07.679, M07.68, M07.69, M08.00, M08.011, M08.012, M08.019, M08.021, M08.022, M08.029, M08.031, M08.032, M08.039, M08.041, M08.042, M08.049, M08.051, M08.052, M08.059, M08.061, M08.062, M08.069, M08.071, M08.072, M08.079, M08.08, M08.09, M08.0A, M08.1, M08.20, M08.211, M08.212, M08.219, M08.221, M08.222, M08.229, M08.231, M08.232, M08.239, M08.241, M08.242, M08.249, M08.251, M08.252, M08.259, M08.261, M08.262, M08.269, M08.271, M08.272, M08.279, M08.28, M08.29, M08.2A, M08.3, M08.40, M08.411, M08.412, M08.419, M08.421, M08.422, M08.429, M08.431, M08.432, M08.439, M08.441, M08.442, M08.449, M08.451, M08.452, M08.459, M08.461, M08.462, M08.469, M08.471, M08.472, M08.479, M08.48, M08.4A, M08.80, M08.811, M08.812, M08.819, M08.821, M08.822, M08.829, M08.831, M08.832, M08.839, M08.841, M08.842, M08.849, M08.851, M08.852, M08.859, M08.861, M08.862, M08.869, M08.871, M08.872, M08.879, M08.88, M08.89, M08.90, M08.911, M08.912, M08.919, M08.921, M08.922, M08.929, M08.931, M08.932, M08.939, M08.941, M08.942, M08.949, M08.951, M08.952, M08.959, M08.961, M08.962, M08.969, M08.971, M08.972, M08.979, M08.98, M08.99, M08.9A, M12.00, M12.011, M12.012, M12.019, M12.021, M12.022,

M12.029, M12.031, M12.032, M12.039, M12.041, M12.042, M12.049, M12.051, M12.052, M12.059, M12.061, M12.062, M12.069, M12.071, M12.072, M12.079, M12.08, M12.09, M12.30, M12.311, M12.312, M12.319, M12.321, M12.322, M12.329, M12.331, M12.332, M12.339, M12.341, M12.342, M12.349, M12.351, M12.352, M12.359, M12.361, M12.362, M12.369, M12.371, M12.372, M12.379, M12.38, M12.39, M12.80, M12.861, M12.862, M12.869, M12.89, M13.0, M25.541, M25.542, M25.549, M26.601, M26.602, M26.603, M26.609, M26.611, M26.612, M26.613, M26.619, M26.621, M26.622, M26.623, M26.629, M26.631, M26.632, M26.633, M26.639, M26.641, M26.642, M26.643, M26.649, M26.651, M26.652, M26.653, M26.659, M32.0, M32.10, M32.11, M32.12, M32.13, M32.14, M32.15, M32.19, M32.8, M32.9, M33.00, M33.01, M33.02, M33.03, M33.09, M33.10, M33.11, M33.12, M33.13, M33.19, M33.20, M33.21, M33.22, M33.29, M33.90, M33.91, M33.92, M33.93, M33.99, M34.0, M34.1, M34.2, M34.81, M34.82, M34.83, M34.89, M34.9, M35.00, M35.01, M35.02, M35.03, M35.04, M35.05, M35.06, M35.07, M35.08, M35.09, M35.0A, M35.0B, M35.0C, M35.1, M35.2, M35.3, M35.4, M35.5, M35.6, M35.9, M36.0, M36.8, M45.0, M45.1, M45.2, M45.3, M45.4, M45.5, M45.6, M45.7, M45.8, M45.9, M45.A0, M45.A1, M45.A2, M45.A3, M45.A4, M45.A5, M45.A6, M45.A7, M45.A8, M45.AB, M46.80, M46.81, M46.82, M46.83, M46.84, M46.85, M46.86, M46.87, M46.88, M46.89, M46.90, M46.91, M46.92, M46.93, M46.94, M46.95, M46.96, M46.97, M46.98, M46.99, M48.8X1, M48.8X2, M48.8X3, M48.8X4, M48.8X5, M48.8X6, M48.8X7, M48.8X8, M48.8X9, R76.81 [Hide]

MCG Health
Ambulatory Care 30th Edition
Copyright © 2026 MCG Health, LLC
All Rights Reserved

Last Update: 1/25/2026 1:30:34 AM
Build Number: 30.0.2026012500524.025256